Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2007

View Archived Issues

Snapshots on AMD-11070, a novel small-molecule CXCR4 inhibitor

Immune responses expanded with Remune(R) during HIV treatment interruption

Atorvastatin may reduce cardiovascular events more than simvastatin

Enterotoxigenic Escherichia coli vaccine reduces diarrhea severity in double-blind trial

Astellas Pharma updates clinical progress of YM-155

Recent Lilly and Merck patents describe new antidiabetic agents

Novel antiinfective agents disclosed in recent patent literature

Recent patents cover new therapeutic agents for cancer

Novel treatments for inflammatory disorders claimed in recent patents

Roche to terminate MAXY-VII collaboration with Maxygen

Adherex outlines achievements of 2006, updates goals for 2007

IRB approval for phase III study of crofelemer in HIV-associated diarrhea

FDA awards orphan drug status to cethromycin for anthrax infection

Curis selects CUDC-101 from targeted cancer drug development platform

Tragara closes Series A financing to support oncology and inflammatory programs

Nektar advances PEG-irinotecan into phase I

Avigen cleared to begin phase II with AV-650 for spasticity and muscle spasms

Difimicin cleared to advance into phase III

Curalogic initiates phase III trial for oral ragweed therapy

GV-1001 studied with chemotherapy for inoperable pancreatic cancer

TG-1042 for cutaneous B-cell lymphoma in phase II trial

C1-INH meets primary endpoint in acute HAE study

Phase II results for Aridol in COPD

Identification of a novel cdk5/p25 inhibitor potentially useful for Alzheimer's disease

Transtec more effective and better tolerated than morphine

Japanese launch for Copegus in chronic hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...